Drug Safety Board Will Lead To More Advisory Panel Meetings – FDA’s Galson
This article was originally published in The Tan Sheet
Executive Summary
The advent of FDA's Drug Safety Oversight Board likely will lead to an increase in the number of advisory committee meetings, Center for Drug Evaluation & Research Acting Director Steven Galson said at a meeting of FDA's Science Board April 15